Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

757
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
757
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

823
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
823
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

975
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
975
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

352
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
352
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

561
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
561

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phage intervention improves colitis and response to corticosteroids by attenuating virulence of Crohn's disease-associated bacteria.

Science translational medicine·2026
Same author

Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis.

Gut·2026
Same author

β-Glucan and Inulin Estimated Intake Are Associated With Reduced Risk of Crohn's Disease, Improved Gut Barrier and Systemic Inflammation Markers, and Multi-Omic Signatures in a High-Risk Cohort.

Gastroenterology·2026
Same author

Interleukin23 Receptor Genetic Variants Associate With Crohn's Disease Risk and Microbiome Changes in Healthy First-Degree Relatives.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

medRxiv : the preprint server for health sciences·2026
Same author

Fecal Microbiota Transplantation for Symptom Improvement in Patients With Irritable Bowel Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Gastroenterology·2026

Related Experiment Video

Updated: Dec 25, 2025

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

966

Proton pump inhibitors for functional dyspepsia.

Maria Ines Pinto-Sanchez1, Yuhong Yuan1, Premysl Bercik1

  • 1Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, ON, Canada.

The Cochrane Database of Systematic Reviews
|March 9, 2017
PubMed
Summary

Proton pump inhibitors (PPIs) offer a slight benefit in relieving functional dyspepsia (FD) symptoms compared to placebo, with similar efficacy to H2 receptor antagonists and prokinetics. These drugs are well-tolerated and effective for FD treatment.

More Related Videos

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.2K
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.9K

Related Experiment Videos

Last Updated: Dec 25, 2025

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

966
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.2K
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.9K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Functional dyspepsia (FD) is characterized by persistent or recurrent epigastric pain without an identifiable organic cause.
  • Proton pump inhibitors (PPIs) are used for FD, but their effectiveness is debated.
  • Long-term PPI use carries potential risks, necessitating careful consideration of treatment indications.

Purpose of the Study:

  • To systematically review the efficacy of PPIs in improving global dyspepsia symptoms and quality of life.
  • To compare PPIs against placebo, H2 receptor antagonists (H2RAs), and prokinetics in FD patients.
  • To evaluate PPIs in adults diagnosed with FD using validated criteria.

Main Methods:

  • A systematic review of randomized controlled trials (RCTs) was conducted.
  • Searches included major electronic databases, grey literature, and clinical trial registries up to February 2016.
  • Data on dyspeptic symptoms, quality of life, and adverse events were extracted from 23 RCTs involving 8759 participants.

Main Results:

  • PPIs showed a slight, moderate-quality evidence benefit over placebo for overall dyspepsia symptom relief (NNTB 13).
  • Evidence suggests PPIs may be slightly more effective than H2RAs (low quality) and prokinetics (low quality).
  • No significant differences in adverse events were observed between PPIs and comparators.

Conclusions:

  • PPIs are effective for functional dyspepsia treatment, irrespective of dose or duration, when compared to placebo.
  • PPIs may offer a slight advantage over H2RAs, though evidence is limited.
  • While PPIs appear well-tolerated, their clinical benefit in FD is modest.